- Trial phase
- Approved
- Time to market
- Already on the market, FDA-approved since 2007 (Exforge) and 2009 (Exforge HCT)
- Why 2/10
- No hard, dated catalyst exists for Exforge in the next ~12 months, it is a legacy, already-approved (FDA 2007) hypertension brand inside a mega-cap, with no pending PDUFA, pivotal readout, or label-expansion decision in local data, so the score reflects a minor, catalyst-free program rather than a binary event.
There is nothing tradeable in Exforge itself: the approval binary passed in 2007 and the brand is long generic-eroded, so watch NVS for pipeline events (oncology/immunology readouts), not this drug.
Price Chart
Executive Summary
Exforge is a Novartis-branded blood-pressure combination drug that was FDA-approved on 2007-06-20, with a three-drug version (Exforge HCT) approved 2009-04-30, both recorded as NVS FDA-approval catalysts in local SecBot data. For a mega-cap like Novartis (ADRs at $156.24; analyst consensus "hold"), Exforge is a small, mature, off-patent legacy product with no scheduled regulatory catalyst, hence the neutral, low-impact read.
How It Works
Exforge is a fixed-dose combination pill for high blood pressure, pairing two older blood-pressure-lowering medicines: a calcium-channel blocker (amlodipine, which relaxes blood vessels) and an angiotensin-receptor blocker (valsartan, which blocks a hormone that constricts vessels). Combining them lowers blood pressure more than either alone.
Trial Status
No active clinical development: local SecBot data shows only historical FDA-approval catalyst records (Exforge 2007-06-20; Exforge HCT 2009-04-30) and no Exforge Phase 2/3 trials, recent FDA actions, or press releases in the last year.
The Two-Sided Case
Upcoming Catalysts
- None specific to Exforge; local data lists no scheduled FDA catalysts for NVS in the next 90 days, watch Novartis quarterly 6-K filings for overall portfolio updates instead.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
NOVARTIS AG 6-K NVS ·Originating report